You are not currently logged in.
Access JSTOR through your library or other institution:
If You Use a Screen ReaderThis content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
The Tylenol Incident, Ensuing Regulation, and Stock Prices
Thomas D. Dowdell, Suresh Govindaraj and Prem C. Jain
The Journal of Financial and Quantitative Analysis
Vol. 27, No. 2 (Jun., 1992), pp. 283-301
Published by: Cambridge University Press on behalf of the University of Washington School of Business Administration
Stable URL: http://www.jstor.org/stable/2331372
Page Count: 19
You can always find the topics here!Topics: Drug regulation, Industrial regulation, Pharmaceutical industry, Stock prices, Financial regulation, Pharmaceutical preparations, Packaging, Price regulation, Business structures, Aviation regulation
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Preview not available
The much publicized Tylenol incident in 1982 led to stringent packaging regulations for over-the-counter pharmaceutical drugs. The sudden incident and the swift progression of associated events offer a unique opportunity to assess the wealth effects of the resultant regulations. The market value of common stock of Johnson & Johnson, makers of Tylenol, declined by approximately 29 percent, amounting to $2.31 billion. Although other firms in the industry also suffered significantly, their share price decline did not occur around the Tylenol incident but occurred around the subsequent packaging regulation proceedings. On average, 28 other pharmaceutical firms analyzed in this study experienced a decline of $310 million per firm, or a total of about $8.68 billion. The results suggest that the regulation had a significant negative effect on the common stock prices of firms in the pharmaceutical industry.
The Journal of Financial and Quantitative Analysis © 1992 University of Washington School of Business Administration